Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Exclusive-AstraZeneca exploring options for COVID-19 vaccine business - executive

Coronavirus NewsJul 29, 2021 18:16
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

By Alistair Smout and Pushkala Aripaka

LONDON (Reuters) -AstraZeneca is exploring options for the future of its COVID-19 vaccine and expects greater clarity on the matter by the end of 2021, a senior executive said on Thursday, following a series of setbacks in its race to produce a shot for the world.

Executives emphasised it was too early to say what the decision on the vaccine's future or the outcome of the review would be.

AstraZeneca (NASDAQ:AZN) agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.

While a $39 billion dollar deal to buy rare drug firm Alexion (NASDAQ:ALXN) is much more integral to the company's business strategy, the COVID-19 vaccine has quickly become the public face of the company's efforts during the coronavirus pandemic.

"If you ask me, is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years, that big strategic question is under discussion," Ruud Dobber, head of the BioPharmaceuticals business, told Reuters.

A small group of staff reporting to research chief Mene Pangalos and Dobber are looking into this, he said.

"We need to have that discussion with our senior executive team, and then with the board of AstraZeneca. We are exploring different options, but it is far too early at this stage to conclude that (process)," he said.

"Hopefully before the year ends, we will have a better view how to move forward in the next few years."

SETBACKS

Production problems forced the company to cut deliveries to the European Union earlier in the year, prompting the bloc to launch a legal challenge.

The vaccine has also faced age restrictions due to being linked to rare clots and its application for U.S. approval is taking longer than expected.

Chief Executive Pascal Soriot said he had no regrets over getting involved in COVID-19 vaccines as the company has made an "enormous difference".

It has delivered one billion doses around the world globally and is celebrated by the British government as a national success story of the pandemic.

Dobber said that AstraZeneca's "number one commitment" was to deliver hundreds of millions of vaccine doses that were covered by current contracts, but it was open to talks with governments asking the company about supplies for 2022.

"It's not a distraction," he said of the vaccine, adding that data on factors such as the durability of the shots are still being collected from the real-world roll-out of the shot.

"There are still a huge number of basic questions we need to answer, moving forwards, and therefore, we're not in a rush in order to come to a final conclusion about what to do as a next step."

Asked about the future of the vaccine on an analyst call, Soriot played down Dobber's comments.

"We are of course are going to look at the way forward, but we haven't got any specific timeline for this... our priority hasn't been to look at what we're going to do moving forward," he told analysts.

Dobber added that the company would keep its pledge to deliver a broadly available and accessible vaccine. Soriot has said that the vaccine will always be kept affordable for low-income countries, even when the company moves away from a no-profit model.

Results released on Thursday showed sales of the vaccine in the second quarter more than tripled to $894 million from the first three months of the year, making it one of its top-selling products.

But, unlike for rivals including Pfizer (NYSE:PFE), it remains a drag on earnings overall, and Dobber said that if the vaccine business were to be sustainable, the company would have to stop making a loss on it.

"It's not sustainable to do it without profits, but it's too early now to speculate about that," Dobber said.

Exclusive-AstraZeneca exploring options for COVID-19 vaccine business - executive
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
ian Chamberlain
ian Chamberlain Jul 29, 2021 22:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
really????........if it wasn't working, the country would be back in lockdown, and we woukd be seeing 1000 deaths a day.....instead everything is open, and deaths are around 50 a day......I'm my book that's a great success story
Drake Richards
Drake Richards Jul 29, 2021 11:50
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the vaccine doesn't work
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email